AbbVie (ABBV) Return on Capital Employed (2013 - 2026)
AbbVie (ABBV) reported Return on Capital Employed of 16.47% for Q1 2026, up 632.0% year-over-year from 2.25% in Q1 2025, and down 0.99% on a QoQ basis from 16.63% in Q4 2025.
AbbVie (ABBV) has 14 years of Return on Capital Employed data on file, last reported at 16.47% in Q1 2026.
- Quarterly Return on Capital Employed rose 632.0% year-over-year to 16.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16.47% (up 632.0% YoY) and the FY2025 annual result came in at 16.52%, up 702.0% from the prior year.
- Return on Capital Employed slipped to 16.47% in Q1 2026 per ABBV's latest filing, from 16.63% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 16.93% in Q2 2023 and bottomed at 9.09% in Q4 2024.
- The 5-year median for Return on Capital Employed is 14.82% (2023), against an average of 13.9%.
- The widest annual swing landed in 2024, when Return on Capital Employed sank 507 bps; it then surged 754 bps in 2025.
- Tracing ABBV's Return on Capital Employed over 5 years: stood at 16.39% in 2022, then decreased by 20 bps to 13.07% in 2023, then sank by 30 bps to 9.09% in 2024, then surged by 83 bps to 16.63% in 2025, then slipped by 1 bps to 16.47% in 2026.
- Per Business Quant, the three latest ABBV Return on Capital Employed figures stand at 16.47% (Q1 2026), 16.63% (Q4 2025), and 9.4% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -6.84% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.47% |
| Dec 31, 2025 | 16.63% |
| Sep 30, 2025 | 9.40% |
| Jun 30, 2025 | 11.32% |
| Mar 31, 2025 | 10.15% |
| Dec 31, 2024 | 9.09% |
| Sep 30, 2024 | 13.88% |
| Jun 30, 2024 | 11.86% |
| Mar 31, 2024 | 12.75% |
| Dec 31, 2023 | 13.07% |
| Sep 30, 2023 | 14.91% |
| Jun 30, 2023 | 16.93% |
| Mar 31, 2023 | 14.82% |
| Dec 31, 2022 | 16.39% |
| Sep 30, 2022 | 16.15% |
| Jun 30, 2022 | 16.00% |
| Mar 31, 2022 | 16.50% |
| Dec 31, 2021 | 15.93% |
| Sep 30, 2021 | 13.85% |
| Jun 30, 2021 | 12.90% |
| Mar 31, 2021 | 10.00% |
| Dec 31, 2020 | 9.36% |
| Sep 30, 2020 | 9.22% |
| Jun 30, 2020 | 11.42% |
| Mar 31, 2020 | 18.42% |
| Dec 31, 2019 | 22.12% |
| Sep 30, 2019 | 16.14% |
| Jun 30, 2019 | 17.81% |
| Mar 31, 2019 | 14.70% |
| Dec 31, 2018 | 14.02% |
| Sep 30, 2018 | 21.86% |
| Jun 30, 2018 | 21.01% |
| Mar 31, 2018 | 18.94% |
| Dec 31, 2017 | 17.95% |
| Sep 30, 2017 | 18.36% |
| Jun 30, 2017 | 18.02% |
| Mar 31, 2017 | 12.26% |
| Dec 31, 2016 | 12.13% |
| Sep 30, 2016 | 11.52% |
| Jun 30, 2016 | 12.08% |
| Mar 31, 2016 | 15.48% |
| Dec 31, 2015 | 13.99% |
| Sep 30, 2015 | 7.67% |
| Jun 30, 2015 | 8.85% |
| Mar 31, 2015 | 23.34% |
| Dec 31, 2014 | 20.56% |
| Sep 30, 2014 | 24.24% |
| Jun 30, 2014 | 25.61% |
| Mar 31, 2014 | 25.14% |
| Dec 31, 2013 | 25.93% |
| Sep 30, 2013 | 28.06% |
| Jun 30, 2013 | 29.78% |
| Mar 31, 2013 | 30.23% |